Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IOBT
Upturn stock ratingUpturn stock rating

IO Biotech Inc (IOBT)

Upturn stock ratingUpturn stock rating
$0.83
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/14/2025: IOBT (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -58.56%
Avg. Invested days 19
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 56.85M USD
Price to earnings Ratio -
1Y Target Price 9
Price to earnings Ratio -
1Y Target Price 9
Volume (30-day avg) 258891
Beta 0.42
52 Weeks Range 0.66 - 1.95
Updated Date 01/14/2025
52 Weeks Range 0.66 - 1.95
Updated Date 01/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.29

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -50.98%
Return on Equity (TTM) -87.66%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -21317360
Price to Sales(TTM) -
Enterprise Value -21317360
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 1.36
Shares Outstanding 65880900
Shares Floating 27841933
Shares Outstanding 65880900
Shares Floating 27841933
Percent Insiders 0.24
Percent Institutions 76.79

AI Summary

IO Biotech Inc.: A Comprehensive Overview

Company Profile:

History and Background: IO Biotech Inc. (IOBT), formerly known as Agensys, Inc., was founded in 1998 and is headquartered in San Diego, California. The company focuses on the discovery and development of novel cancer immunotherapy products. Its lead product candidate, IO102-IO103, is a proprietary bispecific antibody designed to target and activate the immune system to fight EGFR-expressing tumors.

Core Business Areas: IOBT's core business areas include:

  • Discovery and development of next-generation cancer immunotherapies
  • Clinical research and development of IO102-IO103
  • Collaboration with leading research institutions and pharmaceutical companies

Leadership Team and Corporate Structure:

  • Dr. Gary Johnson, President and Chief Executive Officer
  • Dr. John F. DiPersio, Chief Medical Officer
  • Dr. Robert Li, Chief Scientific Officer
  • Ms. Kathy Galvez, Chief Financial Officer
  • The Board of Directors consists of experienced professionals with expertise in biotechnology, medicine, and finance.

Top Products and Market Share:

Top Products:

  • IO102-IO103: A bispecific antibody targeting EGFR-expressing tumors, currently in Phase 2 clinical trials.

Market Share:

  • IO102-IO103 is not yet approved for commercial use, so it does not currently hold any market share.
  • The global market for cancer immunotherapy is expected to reach $130.8 billion by 2025, with EGFR-targeted therapies representing a significant segment.
  • IOBT faces competition from established players like Bristol-Myers Squibb (BMY), Merck (MRK), and Roche (RHHBY) in the EGFR-targeted therapy market.

Total Addressable Market:

The total addressable market (TAM) for IO102-IO103 is estimated to be approximately 500,000 patients with EGFR-expressing tumors globally.

Financial Performance:

Recent Financial Performance:

  • IOBT is a clinical-stage company with no product currently approved for commercial use.
  • Revenue for 2022 was $4.2 million, primarily from collaboration agreements and research grants.
  • The company reported a net loss of $48.5 million in 2022.

Financial Health:

  • IOBT has a strong cash position of $213.4 million as of December 31, 2022.
  • The company is currently funded through its cash reserves and collaborations.

Dividends and Shareholder Returns:

  • IOBT does not currently pay dividends as it is focused on reinvesting profits into research and development.
  • Shareholder returns have been negative in recent years due to the company's early-stage development and lack of product revenue.

Growth Trajectory:

Historical Growth:

  • IOBT has made significant progress in advancing its lead product candidate, IO102-IO103, into Phase 2 clinical trials.
  • The company has also expanded its intellectual property portfolio through patents and collaborations.

Future Growth:

  • IOBT's growth prospects are contingent on the success of its clinical trials and regulatory approvals.
  • The company is also exploring opportunities to expand its pipeline and enter new markets.

Market Dynamics:

Industry Overview:

  • The cancer immunotherapy market is rapidly growing due to advancements in research and technology.
  • Key trends include the development of personalized therapies, combination therapies, and early-stage cancer detection.

Competitive Landscape:

  • IOBT faces competition from established pharmaceutical companies and emerging biotechnology startups.
  • The company differentiates itself through its proprietary bispecific antibody platform and its focus on EGFR-expressing tumors.

Competitors:

  • Bristol-Myers Squibb (BMY)
  • Merck (MRK)
  • Roche (RHHBY)
  • Amgen (AMGN)
  • Pfizer (PFE)

Competitive Advantages:

  • Proprietary bispecific antibody platform
  • Focus on EGFR-expressing tumors
  • Experienced management team
  • Strong cash position

Challenges and Opportunities:

Challenges:

  • Clinical trial risk
  • Regulatory approvals
  • Competition from established players

Opportunities:

  • Growing cancer immunotherapy market
  • Unmet medical need in EGFR-expressing tumors
  • Potential for strategic partnerships

Recent Acquisitions (last 3 years):

  • IOBT has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Based on an analysis of various factors, including financial health, market position, and future prospects, IOBT receives an AI-based fundamental rating of 6.5 out of 10.

Sources and Disclaimers:

  • Financial data from IOBT's annual reports and filings with the U.S. Securities and Exchange Commission (SEC)
  • Market data from industry reports and analysis

Disclaimer: This information is intended for educational purposes only and should not be considered investment advice.

Conclusion:

IO Biotech Inc. is a clinical-stage biotechnology company with a promising pipeline of cancer immunotherapy products. The company's lead candidate, IO102-IO103, has the potential to address a significant unmet medical need in EGFR-expressing tumors. However, IOBT faces competition from established players and its future success depends on the outcome of its clinical trials and regulatory approvals.

About NVIDIA Corporation

Exchange NASDAQ
Headquaters -
IPO Launch date 2021-11-05
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 74
Full time employees 74

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​